AbbVie's SWOT analysis: stock outlook strong despite humira loss

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates ...
Seeking Alpha

AbbVie: The Humira Loss May Be Fully Priced In After All

The US FDA has already approved two directly interchangeable biosimilars to ABBV's Humira, namely Boehringer Ingelheim's Cyltezo and PFE's ABRILADA. The impact on ABBV's sales may be great, since its ...
FiercePharma

AbbVie's Humira loses some ground in high-stakes battle against biosimilars: report

Even through an onslaught of biosimilar launches that began early last year, AbbVie’s big-selling Humira has been able to retain most of its lucrative market. Still, though, the drug’s star power is ...
STAT

Pharmalittle: We’re reading about a Novo weight loss study, a GSK vaccine failure, and more

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Investopedia

AbbVie Q1 Earnings to Shine Light on Loss of Humira Patent

Sales of Humira, which accounted for more than one-third of the company's revenue in 2022, are expected to nosedive Kevin George is a crypto writer and editor for Investopedia. He holds a master's ...
NPR

AbbVie's blockbuster drug Humira finally loses its 20-year, $200 billion monopoly

After 20 years and $200 billion in revenue, Humira — an injectable treatment for rheumatoid arthritis and several other autoimmune conditions — has lost its monopoly. Early Tuesday morning, California ...
BioWorld

Move over, Humira, there’s a new mega-blockbuster in town

There was a time not that long ago when Merck & Co. Inc.’s Keytruda (pembrolizumab), with its multiple cancer indications, was seen as the heir apparent to Humira’s title of the biggest blockbuster ...
OPB

AbbVie’s blockbuster drug Humira finally loses its 20-year, $200B monopoly

JB Reed / Bloomberg via Getty Images After 20 years and $200 billion in revenue, Humira — an injectable treatment for rheumatoid arthritis and several other autoimmune conditions — has lost its ...